{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:02:22Z","timestamp":1788292942595,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Much research has been conducted into the role and safety of anti-amyloid monoclonal antibodies on the progression of Alzheimer\u2019s disease (AD). Despite the historical approval of three drugs by the US Food and Drug Administration for the treatment of early AD, there remains other potential treatment, which is yet to be approved or further developed. This systematic review explores the efficacy of anti-amyloid monoclonal antibodies in the treatment of early AD from reported clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Authors conducted a systematic search of MEDLINE and Embase. Screening was carried out by two authors and cross-checked thereafter. Clinical changes in cognition and objective measures such as cerebrospinal fluid biomarkers and imaging constituted primary and secondary outcomes, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our search yielded 14 randomized controlled trials; the primary focus of the included trials is amyloid-\u03b2. The monoclonal antibodies reported in this review are: lecanemab, aducanumab, crenezumab, solanezumab, donanemab, bapineuzumab, and gantenerumab. The most common finding among the trials is the lack of statistically significant results in measures of clinical outcomes, (e.g., Clinical Dementia Rating Scale-Sum of Boxes, AD Assessment Scale-Cognitive Subscale). However, specific trials investigating lecanemab, aducanumab, and donanemab demonstrated promising improvements in clinical cognition. Results related to secondary outcomes were also mixed, but showed more positive findings across the included trials. Overall, primary outcomes were inconsistent with secondary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings highlight the need to consider the complex pathophysiology of AD in treatment development. Focusing solely on the amyloid-beta hypothesis may be inadequate; further research is necessary to understand the underlying mechanisms and develop treatments for the multifactorial nature of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_547_24","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T02:00:10Z","timestamp":1746842410000},"page":"333-343","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer\u2019s Dementia: A Systematic Review"],"prefix":"10.4103","volume":"28","author":[{"given":"Alyaa","family":"Mostafa","sequence":"first","affiliation":[{"name":"Postgraduate Medical Education, Manor Hospital, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Tiu","sequence":"additional","affiliation":[{"name":"Postgraduate Medical Education, The Royal Wolverhampton Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farooq","family":"Khan","sequence":"additional","affiliation":[{"name":"Birmingham and Solihull Mental Health Foundation Trust, United Kingdom"},{"name":"West Midlands Clinical Network and Improvement, National Health Service, England"},{"name":"Aston Medical School, Aston University, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrath A","family":"Baig","sequence":"additional","affiliation":[{"name":"Birmingham and Solihull Mental Health Foundation Trust, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"313","DOI":"10.14283\/jpad.2021.15","article-title":"The epidemiology of Alzheimer's disease modifiable risk factors and prevention","volume":"8","author":"Zhang","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1017\/S135561771700100X","article-title":"Alzheimer's disease:Past, present, and future","volume":"23","author":"Bondi","year":"2017","journal-title":"J Int Neuropsychol Soc"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","article-title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks:A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","volume":"68","author":"Avgerinos","year":"2021","journal-title":"Ageing Res Rev"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"870517","DOI":"10.3389\/fnagi.2022.870517","article-title":"Impact of Anti-amyloid-\u03b2 monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease:A Focus on aducanumab and lecanemab","volume":"14","author":"Shi","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jama.2024.13389","article-title":"FDA greenlights second Alzheimer Drug, donanemab","volume":"332","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement:An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2:A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"Van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's Disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer Disease:The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease:Two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/awn256","article-title":"Oskar Fischer and the study of dementia","volume":"132","author":"Goedert","year":"2008","journal-title":"Brain"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/biomedicines7040097","article-title":"Reasons for failed trials of disease-modifying treatments for alzheimer disease and their contribution in recent research","volume":"7","author":"Yiannopoulou","year":"2019","journal-title":"Biomedicines"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/JAD-215699","article-title":"Alzheimer's disease:Key insights from two decades of clinical trial failures","volume":"87","author":"Kim","year":"2022","journal-title":"J Alzheimer's Dis"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"e053012","DOI":"10.1136\/bmjopen-2021-053012","article-title":"Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia:A systematic review with individual patient data network meta-analysis","volume":"12","author":"Veroniki","year":"2022","journal-title":"BMJ Open"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"848215","DOI":"10.3389\/fnins.2022.848215","article-title":"Acu193:An immunotherapeutic poised to test the amyloid \u03b2 oligomer hypothesis of alzheimer's disease","volume":"16","author":"Krafft","year":"2022","journal-title":"Front Neurosci"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/pharmaceutics16010060","article-title":"Monoclonal antibody therapy in alzheimer's disease","volume":"16","author":"Nea\u0163u","year":"2023","journal-title":"Pharmaceutics"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"e12465","DOI":"10.1002\/trc2.12465","article-title":"Alzheimer's disease drug development pipeline:2024","volume":"1","author":"Cummings","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01484-7","article-title":"Amyloid \u03b2-based therapy for Alzheimer's disease:Challenges, successes and future","volume":"8","author":"Zhang","year":"2023","journal-title":"Sig Transduct Target Ther"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_547_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:43:21Z","timestamp":1787773401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_547_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_547_24","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-07-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}